A company driven to create positive change and reduce the impact of disease on people’s lives
Nykode Therapeutics is an Oslo-based clinical-stage biopharmaceutical platform company founded in 2006. Our bold aim is to generate game-changing therapeutics to treat cancers and infectious diseases with a high unmet medical need.
With our unique and innovative modular vaccine technology, we’re specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting immune responses.
Leading the way with our pioneering vaccines
VB10.16
Currently in Phase 2 trials for the treatment of cervical cancer, VB10.16 is our therapeutic vaccine for the treatment of human papillomavirus 16-induced malignancies.
VB10.NEO
The cancer neoantigen vaccine, VB10.NEO, is one of our lead product candidates and is exclusively out-licensed to Genentech. It is currently in Phase 1b trials for the treatment of locally advanced and metastatic tumors and Phase 1/2a trials for the treatment of melanoma, lung, head and neck, renal, and bladder cancers.
COVID-19 vaccine
2021 has seen us initiating a Phase 1/2 trial with our two next-generation COVID-19 vaccine candidates.
Empowered by our long-standing partnerships
In our mission to bring our discoveries to the people who need them, we are proud to collaborate with world-class organizations. In oncology, our partners are Roche, Genentech, and Nektar Therapeutics. We have a multi-target collaboration with Regeneron within oncology and infectious diseases. For COVID-19 vaccine development, we have a strong relationship with Adaptive Biotechnologies.
